Bridge Therapeutics, Inc. (“Safe alternatives to Opioids”) is a quick-to-revenue biopharma company based in Birmingham, Alabama, which is developing a superior delivery of the addiction drug Suboxone ($3B market, 3M patients) and a stronger & safer therapy for moderate to severe chronic pain than Opioids ($15B, 30M). Our addiction drug Bunalz (buprenorphine/naloxone) is administered in 3‑seconds versus 6-16 minutes for competing formulations. It should resolve mouth irritation problems (22% of patients) and aid with “Observed Dosing” in prisons. Our pain drug Bucam (buprenorphine/meloxicam) gives better pain relief than fentanyl without the overdose risk.
Customers: Primary purchasers will be doctors, pharmacy wholesalers/distributors, private insurance (e.g., Express Scripts) and public insurance.
Management team strengths include extensive experience in pharmaceutical formulation development and subsequent FDA approval, fundraising for startup companies, and expertise in regulatory affairs and clinical research (~160 clinical trials).
Support team strengths include extensive experience in FDA operations (Division Head for Analgesia & Addiction), and expertise in the research and treatment of addiction and pain. To facilitate sales within 12 months, the company has hired a market access consultancy to plan the launch.
Funding: The company has already raised over $5 million.
Exit opportunities include IPO, licensing, trade sale or acquisition.
Please discover more news at their website https://www.bridgetherapeutics.com/news/
Buprenorphine is a treatment for opioid addiction designed to curb cravings and reduce overdoses. France changed the law in the 1990s to allow all practitioners to prescribe it and the cost is covered under the country’s universal health care.
P: 941-920-3139 | 877-223-6949
E: [email protected]